Clear Street Group Inc. Buys Shares of 1,016,000 Novo Nordisk A/S $NVO

Key Points

• Clear Street Group established a new position of 1,016,000 shares of Novo Nordisk (NYSE:NVO) in Q3, worth about $56.4 million and representing roughly 0.2% of its portfolio (its 28th-largest holding).
• Novo Nordisk is facing near-term regulatory and legal pressure after the FDA issued a warning about unreported semaglutide adverse events and an investor class‑action/investigation notice was announced.
• Sell‑side sentiment is centered on a consensus “Hold” (4 Buys vs. 19 Holds) with an average price target of $49.93; the company recently beat quarterly EPS and revenue estimates while trading well below its 52‑week high.

Clear Street Group Inc. purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,016,000 shares of the company's stock, valued at approximately $56,378,000. Novo Nordisk A/S makes up about 0.2% of Clear Street Group Inc.'s investment portfolio, making the stock its 28th biggest holding.

Several other institutional investors and hedge funds also recently made changes to their positions in NVO. Revolve Wealth Partners LLC lifted its holdings in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after acquiring an additional 200 shares in the last quarter. AQR Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company's stock worth $4,312,000 after acquiring an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC raised its position in shares of Novo Nordisk A/S by 18.2% during the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company's stock worth $712,000 after purchasing an additional 1,587 shares during the period. Foundations Investment Advisors LLC raised its position in shares of Novo Nordisk A/S by 50.8% during the second quarter. Foundations Investment Advisors LLC now owns 14,738 shares of the company's stock worth $1,017,000 after purchasing an additional 4,964 shares during the period. Finally, Security Financial Services INC. lifted its holdings in shares of Novo Nordisk A/S by 24.2% during the 2nd quarter. Security Financial Services INC. now owns 6,215 shares of the company's stock valued at $429,000 after purchasing an additional 1,212 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Analyst Ratings Changes

Several brokerages recently issued reports on NVO. Nordea Equity Research lowered Novo Nordisk A/S to a "hold" rating in a research report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Monday, February 23rd. Weiss Ratings raised shares of Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, February 5th. Morgan Stanley upgraded shares of Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price target for the company in a report on Tuesday, March 3rd. Finally, Zacks Research upgraded shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, March 10th. Four research analysts have rated the stock with a Buy rating and nineteen have assigned a Hold rating to the company. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Hold" and an average price target of $49.93.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo’s deal with telehealth/retail player Hims & Hers could broaden channels for GLP‑1 distribution and shift competitive dynamics in the obesity market; Hims shares have surged on the tie-up. Hims shares set for best week on record after new Novo Nordisk deal
• Positive Sentiment: Novo’s partnership with the WHO Foundation to support cardio‑renal‑metabolic programs expands its public‑health footprint and may support long‑term access and reputation in emerging markets. Novo Nordisk WHO Partnership Links Global Health Push With Valuation Story
• Neutral Sentiment: Zacks moved NVO from “strong sell” to “hold,” which slightly reduces near‑term sell‑side pressure but is not a bullish upgrade. Zacks.com
• Neutral Sentiment: Broader health‑care weakness today (NYSE Health Care Index decline) is adding to headline pressure across large pharma names, including NVO. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: The FDA issued a warning to Novo Nordisk about unreported semaglutide adverse events — the clearest near‑term catalyst for the share decline as it raises risks of inspections, disclosures, labeling changes, prescribing impacts and regulatory enforcement. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: An investor class‑action/investigation notice (Pomerantz) has been announced, increasing legal risk and potential future claims tied to the disclosure of safety events. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and negative press—plus reporting that Novo Holdings’ assets shrank after the stock slump—are reinforcing selling momentum and investor concern about valuation and control‑group exposure. Novo Nordisk stock slump hits value of controlling shareholder

Novo Nordisk A/S Stock Down 0.1%

NYSE:NVO opened at $37.99 on Friday. The stock has a 50-day simple moving average of $50.14 and a 200 day simple moving average of $51.77. Novo Nordisk A/S has a 52-week low of $35.85 and a 52-week high of $82.57. The company has a market cap of $169.61 billion, a PE ratio of 10.95 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to analysts' expectations of $11.97 billion. On average, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The firm also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be given a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S's payout ratio is currently 52.74%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.